AI Article Synopsis
Article Abstract
Objective: Cisplatin is one of efficacious medicines for TGCT, but is not in 18 WHO EML now. The Union for International Cancer Control recommended cisplatin to the 19 WHO EML for TGCT. To evaluate the effectiveness, safety and cost of cisplatin for TGCT according to the requirements of WHO EML Expert Committee, and to provide the evidence whether cisplatin should be included in WHO EML.
Method: We searched The Cochrane Library, PubMed, EMbase, NHS EED, US National Guideline Clearinghouse (NGC) and WHO guidelines. Guidelines and systematic reviews (SRs) on cisplatin for TGCT were included. Two reviewers selected studies and extracted relevant information independently. Quality of SRs was appraised through AMSTAR.
Results: Seven guidelines and four SRs were included in this rapid review. Quality of SRs was moderate according to AMSTAR. The results showed that: (a) effectiveness: cisplatin-based chemotherapy significantly improved in response rates and overall survival for more advanced disease (stage II and stage III). Bleomycin, etoposide, and cisplatin (BEP)-one of the most widely used of cisplatin-based chemotherapy regimens should be considered as the standard treatment of good-prognosis patients with survival rates of 90% and as the best option for intermediate- or poor-prognosis patients with survival rates of 75% and 50%, respectively. (b) Safety: nephrotoxicity, ototoxicity and peripheral neuropathy are common adverse effects of cisplatin. (c) Cost: there was no relevant study about cost of cisplatin for TGCT. But the affordability of cispaltin is good for Chinese patients, due to it is in health insurance directory of China.
Conclusions: We recommend cisplatin to be listed in 19 WHO EML for TGCT, due to adequate evidence of effectiveness and good affordability.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jebm.12210 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mitochondrial genome variability and metabolic alterations reveal new biomarkers of resistance in testicular germ cell tumors.
Cancer Drug Resist
December 2024
Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava 84505, Slovak Republic.
Mutations in the mitochondrial (mt) genome contribute to metabolic dysfunction and their accumulation relates to disease progression and resistance development in cancer cells. This study explores the mutational status of the mt genome of cisplatin-resistant -sensitive testicular germ cell tumor (TGCT) cells and explores its association with their respiration parameters, expression of respiratory genes, and preferences for metabolic pathways to reveal new markers of therapy resistance in TGCTs. Using Illumina sequencing with Twist Enrichment Panel, the mutations of mt genomes of sensitive 2102EP, H12.
View Article and Find Full Text PDFThe New Tumour Biomarker miRNA-371-3p Influences Cisplatin Sensitivity of Testicular Germ Cell Tumour Cell Lines.
J Cell Mol Med
December 2024
Department of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany.
Cisplatin is used to treat a variety of malignancies, including testicular germ cell tumours (TGCTs). Although cisplatin-based chemotherapy yields high response rates, a subset of patients develop cisplatin resistance, limiting treatment options and worsening prognosis. Therefore, there is a high clinical need for new therapeutic strategies targeting cisplatin-resistant TGCTs.
View Article and Find Full Text PDFLongitudinal Assessment of Cognitive Function in Survivors of Testicular Germ Cell Tumor.
Eur Urol Oncol
December 2024
2nd Department of Oncology, Comenius University and National Cancer Institute, Bratislava, Slovakia; Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia. Electronic address:
Background And Objective: Survivors of testicular germ cell tumor (TGCT) may experience long-term cognitive changes. The aim of our prospective study was to longitudinally assess cognitive function among TGCT survivors to identify potential lasting cognitive changes over a period of 5 yr.
Methods: TGCT survivors (n = 151) completed Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) questionnaires annually, with median time to first follow-up visit (FUV) of 8 (range 4-24) yr since completion of treatment.
PARP inhibitors in testicular germ cell tumors: what we know and what we are looking for.
Front Genet
November 2024
Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy.
Testicular germ cell tumors (TGCTs), the most common malignancies affecting young men, are characterized by high sensitivity to cisplatin-based chemotherapy, which leads to high cure rates even in metastatic disease. However, approximately 30% of patients with metastatic TGCTs relapse after first-line treatment and those who can be defined as platinum-refractory patients face a very dismal prognosis with only limited chemotherapy-based treatment options and an overall survival of few months. Hence, to understand the mechanisms underlying cisplatin resistance is crucial for developing new treatment strategies.
View Article and Find Full Text PDFExploiting potential molecular compounds for treating testicular seminoma by targeting immune related genes.
Cell Commun Signal
November 2024
Department of Urology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Article Synopsis
- Advanced seminoma patients face a serious challenge with up to 30% exhibiting resistance to cisplatin, leading to a high mortality risk, and limited treatment options beyond traditional therapies like chemotherapy and radiotherapy.
- A study utilized advanced statistical methods to identify immune-related genes, leading to the development of a prognostic signature that predicts patient survival more accurately than existing risk factors.
- Results indicated that patients identified as high-risk had significantly lower progression-free survival, and certain molecular compounds could effectively target the identified genes, suggesting potential for immunotherapy in these patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!